XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate Alzheimer’s disease, according to interim results of a clinical trial. Specifically, the Phase 1b clinical trial (NCT03943264) shows evidence that XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by magnetic resonance imaging (MRI). XPro1595 was designed to lower inflammation by selectively neutralizing soluble tumor necrosis factor (sTNF), an inflammatory cell signaling molecule, or cytokine, implicated in Alzheimer's progression, without affecting TNF or TNF receptors present on cells' membranes. TNF levels increase among Alzheimer's patients and mark an earlier step in progression than the characteristic clumps of misfolded proteins known as amyloid plaques, which form later in patients' brains. Neuroinflammation has been shown to play a role in the loss of nerve signaling, nerve cell death, cognitive impairment, and plaque formation. The Phase 1b trial is enrolling adults with mild to moderate Alzheimer's disease who show signs of inflammation (assessed via blood test) at six locations in Australia. More information on enrollment can be found here.